How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors

키워드

참고문헌 (36)

1. Ference BA, "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 38, pp.2459~2472 (2017)[DOI]
2. Sampson UK, "Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges", Curr Atheroscler Rep, 14, pp.1~10 (2012)[DOI]
3. Roth GA, "Global and regional patterns in cardiovascular mortality from 1990 to 2013", Circulation, 132, pp.1667~1678 (2015)[DOI]
4. Abifadel M, "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia", Nat Genet, 34, pp.154~156 (2003)[DOI]
5. Cohen JC, "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease", N Engl J Med, 354, pp.1264~1272 (2006)[DOI]
6. Lagace TA, "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice", J Clin Invest, 116, pp.2995~3005 (2006)[DOI]
7. Maron DJ, "Current perspectives on statins", Circulation, 101, pp.207~213 (2000)[DOI]
8. "REPATHA (evolocumab) injection, for subcutaneous use" (2015)[URL]
9. (2015)[URL]
10. "Repatha: EPAR - product information" (2018)[URL]
11. [URL]
12. Schmidt AF, "PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease", Cochrane Database Syst Rev, 4 (2017)
13. Nicholls SJ, "Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial", JAMA, 316, pp.2373~2384 (2016)[DOI]
14. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)[DOI]
15. Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)[DOI]
16. Koren MJ, "Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label osler-1 extension study", JAMA Cardiol, 2, pp.598~607 (2017)[DOI]
17. Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)[DOI]
18. [URL]
19. Ridker PM, "Cardiovascular efficacy and safety of bococizumab in high-risk patients", N Engl J Med, 376, pp.1527~1539 (2017)[DOI]
20. Sabatine MS, "Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial", Am Heart J, 173, pp.94~101 (2016)[DOI]
21. Giugliano RP, "Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial", JAMA Cardiol, 2, pp.1385~1391 (2017)[DOI]
22. Giugliano RP, "Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial", Lancet, 390, pp.1962~1971 (2017)[DOI]
23. Bonaca MP, "Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)", Circulation, 137, pp.338~350 (2018)[DOI]
24. Sabatine MS, "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial", Lancet Diabetes Endocrinol, 5, pp.941~950 (2017)[DOI]
25. Sabatine MS, "Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER", Circulation (2018)
26. Bohula EA, "Inflammatory and cholesterol risk in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)", Circulation (2018)
27. "REPATHA (evolocumab) injection, for subcutaneous use" (2017)[URL]
28. [URL]
29. Schwartz GG, "Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial", Am Heart J, 168, pp.682~689 (2014)[DOI]
30. Roth EM, "Antidrug antibodies in patients treated with alirocumab", N Engl J Med, 376, pp.1589~1590 (2017)[DOI]
31. Ridker PM, "Lipid-reduction variability and antidrug-antibody formation with bococizumab", N Engl J Med, 376, pp.1517~1526 (2017)[DOI]
32. Ridker PM, "Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials", Am Heart J, 178, pp.135~144 (2016)[DOI]
33. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)[DOI]
34. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)[DOI]
35. Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes", N Engl J Med, 375, pp.1834~1844 (2016)[DOI]
36. [URL]

관련 논문AI추천